Calamos Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BSX.PRA
Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A
BSX.PRA
|
+$61M |
| 2 |
RTX Corp
RTX
|
+$38.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$15.5M |
| 4 |
Delta Air Lines
DAL
|
+$14.5M |
| 5 |
SWT
Stanley Black & Decker, Inc.
SWT
|
+$13.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$578M |
| 2 |
AGN
Allergan plc
AGN
|
+$67M |
| 3 |
BDXA
Becton, Dickinson and Company Depositary Shares, each Representing a 1/20th Interest in a Share of 6
BDXA
|
+$51.1M |
| 4 |
Alibaba
BABA
|
+$46.8M |
| 5 |
lululemon athletica
LULU
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.91% |
| 2 | Healthcare | 8.15% |
| 3 | Consumer Discretionary | 7.49% |
| 4 | Financials | 7.2% |
| 5 | Communication Services | 5.9% |
Similar funds
Calamos Advisors's Q2 2020 Portfolio in Review
As of Q2 2020, Calamos Advisors held 803 positions worth $14.1B, up 11% from $12.7B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Calamos Advisors withdrew a net $4.28B in Q2 2020, closing 98 positions and reducing 295 holdings. Its most notable exit was Allergan plc, an estimated $67M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Calamos Advisors opened a new position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A worth $59.7M.
- Calamos Advisors's largest Q2 2020 buy was Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A: 569,916 shares worth $59.7M.
- Calamos Advisors added most to RTX Corp in Q2 2020, an estimated $38.2M increase.
- Calamos Advisors's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $578M.
- Calamos Advisors fully exited Allergan plc in Q2 2020, selling an estimated $67M.
- Calamos Advisors's ten largest holdings make up 20% of its $14.1B portfolio in Q2 2020.
- Calamos Advisors opened 108 new positions and closed 98 in Q2 2020.
- Calamos Advisors's portfolio value rose 11% quarter-over-quarter to $14.1B.
Based on Calamos Advisors's 13F filing for Q2 2020, filed 27 Jul 2020.